Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

FRA:1COV - Deutsche Boerse Ag - DE0006062144 - Common Stock - Currency: EUR

60.48  +0.1 (+0.17%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 1COV. 1COV was compared to 68 industry peers in the Chemicals industry. 1COV has a bad profitability rating. Also its financial health evaluation is rather negative. 1COV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

1COV had negative earnings in the past year.
1COV had a positive operating cash flow in the past year.
In multiple years 1COV reported negative net income over the last 5 years.
In the past 5 years 1COV always reported a positive cash flow from operatings.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

1COV's Return On Assets of -2.78% is on the low side compared to the rest of the industry. 1COV is outperformed by 67.65% of its industry peers.
The Return On Equity of 1COV (-6.10%) is worse than 64.71% of its industry peers.
Industry RankSector Rank
ROA -2.78%
ROE -6.1%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

In the last couple of years the Operating Margin of 1COV has declined.
1COV's Gross Margin of 14.41% is on the low side compared to the rest of the industry. 1COV is outperformed by 75.00% of its industry peers.
In the last couple of years the Gross Margin of 1COV has declined.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.41%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1COV has about the same amount of shares outstanding.
1COV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1COV has an improved debt to assets ratio.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

1COV has an Altman-Z score of 2.22. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of 1COV (2.22) is comparable to the rest of the industry.
1COV has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
1COV's Debt to Equity ratio of 0.31 is fine compared to the rest of the industry. 1COV outperforms 64.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 2.22
ROIC/WACCN/A
WACC6.27%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

1COV has a Current Ratio of 1.32. This is a normal value and indicates that 1COV is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of 1COV (1.32) is worse than 72.06% of its industry peers.
1COV has a Quick Ratio of 1.32. This is a bad value and indicates that 1COV is not financially healthy enough and could expect problems in meeting its short term obligations.
1COV has a worse Quick ratio (0.71) than 83.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.71
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

3

3. Growth

3.1 Past

1COV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.62%.
The Revenue has decreased by -1.38% in the past year.
Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.
EPS 1Y (TTM)-8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.58%
Revenue 1Y (TTM)-1.38%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-9.14%

3.2 Future

1COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.50% yearly.
The Revenue is expected to grow by 1.74% on average over the next years.
EPS Next Y122.42%
EPS Next 2Y88.03%
EPS Next 3Y60.44%
EPS Next 5Y35.5%
Revenue Next Year-0.51%
Revenue Next 2Y2.12%
Revenue Next 3Y2.34%
Revenue Next 5Y1.74%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

1COV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 27.74, 1COV can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, 1COV is valued a bit more expensive than 64.71% of the companies in the same industry.
1COV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.36.
Industry RankSector Rank
PE N/A
Fwd PE 27.74
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as 1COV.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.27
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1COV's earnings are expected to grow with 60.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.03%
EPS Next 3Y60.44%

More info and screens

0

5. Dividend

5.1 Amount

1COV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COVESTRO AG

FRA:1COV (8/7/2025, 1:33:11 PM)

60.48

+0.1 (+0.17%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)N/A N/A
Inst Owners41.76%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.43B
Analysts68.89
Price Target62.93 (4.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-691.25%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-159.74%
EPS beat(4)1
Avg EPS beat(4)-3758.66%
Min EPS beat(4)-13853.1%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4303.1%
EPS beat(12)2
Avg EPS beat(12)-2871.29%
EPS beat(16)4
Avg EPS beat(16)-2153.19%
Revenue beat(2)0
Avg Revenue beat(2)-4.8%
Min Revenue beat(2)-5.09%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-4.72%
Min Revenue beat(4)-6.71%
Max Revenue beat(4)-2.59%
Revenue beat(8)0
Avg Revenue beat(8)-4.65%
Revenue beat(12)2
Avg Revenue beat(12)-2.45%
Revenue beat(16)5
Avg Revenue beat(16)-1.22%
PT rev (1m)-0.04%
PT rev (3m)-0.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-1.73%
Revenue NQ rev (3m)-6.32%
Revenue NY rev (1m)-2.58%
Revenue NY rev (3m)-4.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.74
P/S 0.81
P/FCF N/A
P/OCF 13.94
P/B 1.78
P/tB 2.18
EV/EBITDA 15.27
EPS(TTM)-1.86
EYN/A
EPS(NY)2.18
Fwd EY3.61%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)4.34
OCFY7.17%
SpS74.85
BVpS33.9
TBVpS27.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.78%
ROE -6.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.41%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA 2.09
Cap/Depr 84.99%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion 87.7%
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.71
Altman-Z 2.22
F-Score3
WACC6.27%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.58%
EPS Next Y122.42%
EPS Next 2Y88.03%
EPS Next 3Y60.44%
EPS Next 5Y35.5%
Revenue 1Y (TTM)-1.38%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-9.14%
Revenue Next Year-0.51%
Revenue Next 2Y2.12%
Revenue Next 3Y2.34%
Revenue Next 5Y1.74%
EBIT growth 1Y-134.13%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year364.32%
EBIT Next 3Y92.23%
EBIT Next 5Y53%
FCF growth 1Y-94.44%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y3.27%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%